The race is on for vaccines and treatments for COVID-19. Brian Abrahams, RBC’s Co-Head of Biotechnology Research, has some hope based on what he’s seeing but cautions we’re “in the early innings.” A vaccine is probably not realistic before 2021, he warns. And treatments – antivirals and anti-inflammatories, especially – could be months away. The efficacy of treatments could also vary widely across populations, just as we’re seeing with the virus. A magic bullet for curing coronavirus “is probably wishful thinking.” Even so, the availability of treatments, along with other measures, may slow infections, reduce their severity and enable some return to normalcy.

For more insights about social, economic and technological trends, visit rbc.com/thoughtleadership.